{"entity":{"id":"nct05224141","kind":"trial","name":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","aka":["KEYVIBE-008"],"tldr":"A phase 3 trial of Pembrolizumab, Etoposide, Cisplatin, Atezolizumab and Carboplatin in small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) is a phase 3 interventional study registered as NCT05224141 by Merck Sharp & Dohme LLC, with 460 participants enrolled, started 2022-03-24 and due to reach its primary completion in 2024-06-04. Interventions recorded: Pembrolizumab/Vibostolimab Co-Formulation, Saline placebo, Etoposide, Cisplatin, Atezolizumab and Carboplatin. Results have been posted on the registry.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05224141","url":"https://clinicaltrials.gov/study/NCT05224141"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc","extensive-stage-sclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","topoisomerase-inhibitors"],"targets":[],"drugs":["pembrolizumab","etoposide","cisplatin","atezolizumab","carboplatin"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05224141","phase":"3","setting":"A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)","sponsor":"Merck Sharp & Dohme LLC","started":"2022-03-24","startedType":"actual","yearReported":2025,"enrolled":460,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Survival (OS)","primary":true,"unit":"months","arms":[{"name":"Pembrolizumab/Vibostolimab","n":230,"value":11.5,"note":"95% CI 9.8 to 12.6; Figures from the ClinicalTrials.gov results section (first posted 2025-05-30), not from a publication"},{"name":"Atezolizumab","n":230,"value":12.9,"note":"95% CI 11.6 to 14.8"}],"hr":1.26,"ci":[1,1.59],"p":"0.9762","source":"https://clinicaltrials.gov/study/NCT05224141?tab=results"},{"endpoint":"Progression-Free Survival (PFS)","unit":"months","arms":[{"name":"Pembrolizumab/Vibostolimab","n":230,"value":5.3,"note":"95% CI 4.4 to 5.4; Figures from the ClinicalTrials.gov results section (first posted 2025-05-30), not from a publication"},{"name":"Atezolizumab","n":230,"value":4.5,"note":"95% CI 4.4 to 5.3"}],"hr":1.01,"ci":[0.82,1.23],"p":"0.5316","source":"https://clinicaltrials.gov/study/NCT05224141?tab=results"},{"endpoint":"Objective Response Rate (ORR)","unit":"%","arms":[{"name":"Pembrolizumab/Vibostolimab","n":230,"value":71.7,"note":"95% CI 65.4 to 77.5; Figures from the ClinicalTrials.gov results section (first posted 2025-05-30), not from a publication"},{"name":"Atezolizumab","n":230,"value":74.8,"note":"95% CI 68.7 to 80.3"}],"source":"https://clinicaltrials.gov/study/NCT05224141?tab=results"}]},"route":"/trials/nct05224141/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}